Actively Recruiting
Determinants of Warfarin Metabolism
Led by Hadassah Medical Organization · Updated on 2026-04-21
1000
Participants Needed
1
Research Sites
1421 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
CONDITIONS
Official Title
Determinants of Warfarin Metabolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age range of 20-50 years old
- Healthy individuals without significant disease states
You will not qualify if you...
- Known hypersensitivity to warfarin or phenytoin
- Known hypersensitivity to penicillins or cephalosporins (relevant for dicloxacillin use)
- Presence of significant disease states
- Regular use of medications, including birth control pills
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hadassah Medical Organization
Jerusalem, Israel
Actively Recruiting
Research Team
Y
Yoseph Caraco, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here